Niraparib Tosylate Monohydrate
Salt and hydrate forms alter handling rather than pharmacology, and niraparib tosylate monohydrate carries the therapeutic properties of niraparib itself. The parent compound inhibits poly(ADP-ribose) polymerase, the enzyme family responsible for repairing single-strand breaks in DNA. When that repair route is blocked in a cell already deficient in homologous recombination, unrepaired damage accumulates through replication and the cell dies, the relationship described as synthetic lethality. This dependence on an underlying repair defect is why the class is directed at tumours carrying specific genetic alterations. The salt is recorded with formula C26H30N4O5S and a mass near 510.6 g/mol, and is approved with development completed through the final phase.
A tosylate salt form of niraparib with the same therapeutic properties. A PARP inhibitor that blocks a DNA repair enzyme, causing cancer cells with certain genetic mutations to die.
Peso Molecular
510,6000 g/mol
TPSA
137,00 Ų
Áreas Terapêuticas
Mecanismo de Ação
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
Cc1ccc(S(=O)(=O)O)cc1.NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12.O
InChI
InChI=1S/C19H20N4O.C7H8O3S.H2O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10;/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10);1H2/t14-;;/m1../s1
Molecular Formula
C26H30N4O5S
HBD / HBA
4 / 7
Ligações Rotacionáveis
4
Átomos Pesados
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A tosylate salt form of niraparib with the same therapeutic properties. A PARP inhibitor that blocks a DNA repair enzyme, causing cancer cells with certain genetic mutations to die.
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.
Yes, Niraparib Tosylate Monohydrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989922. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 74763937. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="niraparib-tosylate-monohydrate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/niraparib-tosylate-monohydrate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/niraparib-tosylate-monohydrate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/niraparib-tosylate-monohydrate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="niraparib-tosylate-monohydrate"></drugfyi-drug>